Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




SCHEDULE 13D/A 0001962221-25-000003 0001962221 XXXXXXXX LIVE 1 Common Stock, par value $0.001 per share 11/06/2025 false 0001396814 695127100 Pacira BioSciences, Inc. 2000 SIERRA POINT PARKWAY SUITE 900 BRISBANE CA 94005 Pedro Escudero (305) 549-5081 3350 Virginia Street, Suite 530 Miami FL 33131 0001962221 N Doma Perpetual Capital Management LLC WC N DE 0.00 2936794.00 0.00 2936794.00 2936794.00 N 6.83 IA Y DOMA Perpetual LO Equity Master Fund LP WC N E9 0.00 2936794.00 0.00 2936794.00 2936794.00 N 6.83 PN Y Doma Perpetual Partners GP LLC WC N DE 0.00 2936794.00 0.00 2936794.00 2936794.00 N 6.83 OO Y Pedro Escudero WC PF N X1 159000.00 2777794.00 159000.00 2777794.00 2936794.00 N 6.83 IN Y John Templeton Foundation WC N TN 0.00 812019.00 0.00 812019.00 812019.00 N 1.89 CO John Templeton Foundation beneficially owns Common Shares via its wholly- owned investment holding company, Reliability LLC. Y DOMA2 LLC WC N DE 0.00 2936794.00 0.00 2936794.00 2936794.00 N 6.83 OO Common Stock, par value $0.001 per share Pacira BioSciences, Inc. 2000 SIERRA POINT PARKWAY SUITE 900 BRISBANE CA 94005 This Schedule 13D relates to the Common Shares, with par value $0.001 per share (the "Common Shares"), of Pacira BioSciences, Inc. (the "Issuer"). The address of the principal executive offices of the Issuer is 2000 Sierra Point Parkway, Suite 900, Brisbane, California 94005. This statement is filed by the entities and persons listed below: (i) Doma Perpetual Capital Management LLC ("Doma"), as the investment manager for Doma Perpetual Lo Equity Master Fund LP and the John Templeton Foundation ("The John Templeton Foundation"), with respect to the Common Shares beneficially owned by it; (ii) DOMA Perpetual LO Equity Master Fund LP ("Doma Master Fund"), a Cayman Islands exempted limited partnership, with respect to the Common Shares beneficially owned by it; (iii) Doma Perpetual Partners GP LLC ("Doma GP"), as the general partner of the Doma Master Fund, with respect to the Common Shares beneficially owned by it; (iv) DOMA2 LLC ("Doma 2"), as the managing member of Doma GP, with respect to the Common Shares beneficially owned by it; (v) The John Templeton Foundation, as a discretionary investment management client of Doma, with respect to the Common Shares beneficially owned by it; and (vi) Pedro Escudero ("Mr. Escudero"), individually and as Chief Investment Officer of Doma and sole Manager of Doma 2 with respect to the Common Shares beneficially owned by him. The address of the principal office of each of Doma, Doma Master Fund, Doma GP, Doma2, and Pedro Escudero is 3350 Virgina Street, Suite 530, Miami, FL 33133. The address of the principal office of The John Templeton Foundation is 300 Conshohocken State Road, Suite 500, West Conshohocken, PA 19428. Doma provides investment advisory and management services and acts as the investment manager of Doma Master Fund and The John Templeton Foundation. Doma Master Fund has been formed for the purpose of investing in securities and engaging in all related activities and transactions. Doma GP provides investment management services and serves as the general partner of the Doma Master Fund. Doma 2 is the managing member of Doma GP. The John Templeton Foundation, via its wholly-owned investment holding company, Reliability LLC, invests in securities and engages in all related activities and transactions. Mr. Escudero serves as Chief Executive Officer and Chief Investment Officer of Doma and sole Manager of Doma 2. No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. Mr. Escudero is a citizen of the United States of America. Item 3 is hereby amended by supplementing it with the following language at the end: Additionally, from September 10, 2025, to September 24, 2025, inclusive, Doma on behalf of the Doma Master Fund purchased, with working capital, an additional 161,706 Common Shares, with an aggregate purchase price of $4,285,796, and from October 6, 2025, to October 7, 2025, inclusive, Doma on behalf of The John Templeton Foundation and its wholly-owned investment holding company, Reliability LLC, purchased, with working capital, 76,470 Common Shares for an aggregate purchase price of $1,817,594. All purchases of Common Shares were purchased on the open market. Item 4 is hereby amended, supplemented, and restated in its entirety as follows: The Reporting Persons purchased Common Shares on 8/1/2025, 8/4/2025, and 8/5/2025 with the intent to influence the Issuer, but without the intention to take full control of it. Additional purchases were made in September 2025 and October 2025, for investment purposes and also with the intent to influence the Issuer, but without the intention to take full control of it. The Reporting Persons are recommending to the Board of Directors of the Issuer that they take certain actions. The Reporting Persons sent a letter to the Board of Directors on November 10, 2025 (the "Letter"), which is attached hereto and has been or is being made public. The Reporting Persons are not currently contemplating any changes in the Issuer's management or board composition, but may contemplate such changes if they believe the Common Shares are underperforming. As provided in the Letter, among other recommendations, the Reporting Persons are recommending to the Board of Directors that they engage a banker to explore a sale of the business. Aside from recommendations in the Letter, the Reporting Persons are not currently seeking material changes to the Issuer's operations, policies, or corporate structure, but may seek such changes if they believe the Common Shares are underperforming. Item 5 (a) is hereby amended, supplemented, and restated in its entirety as follows: (a) The percentages used in this Schedule 13D are calculated based upon 43,021,275 outstanding Common Shares of the Issuer as of November 5, 2025, as provided on the cover page of the issuer's Form 10-Q, filed on November 6, 2025. See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Common Shares and percentage of the Common Shares beneficially owned by each of the Reporting Persons. Item 5 (c) is amended and supplemented by adding the following language: On September 10, 2025, through September 24, 2025, inclusive, Doma on behalf of the Doma Master Fund purchased with working capital 161,706.00 Common Shares on the open market for an aggregate purchase price of $4,285,796.70 On October 6, 2025, to October 7, 2025, inclusive, Doma on behalf of The John Templeton Foundation and its wholly-owned investment holding company, Reliability LLC purchased, with working capital, 76,470 Common Shares on the open market for an aggregate purchase price of $1,817,594. Exhibit 99. 1 - Letter to the Board of Directors of Pacira Biosciences Doma Perpetual Capital Management LLC /s/ Pedro Escudero Authorized Signatory 11/10/2025 DOMA Perpetual LO Equity Master Fund LP /s/ Pedro Escudero Authorized Signatory 11/10/2025 Doma Perpetual Partners GP LLC /s/ Pedro Escudero Authorized Signatory 11/10/2025 Pedro Escudero /s/ Pedro Escudero Authorized Signatory 11/10/2025 John Templeton Foundation /s/ Pedro Escudero Authorized Signatory 11/10/2025 DOMA2 LLC /s/ Pedro Escudero Authorized Signatory 11/10/2025